# CJC-1295 vs Ipamorelin: How They Differ in Growth-Hormone Research

**Quick answer:** CJC-1295 and Ipamorelin are both studied for growth-hormone (GH) release, but through two different receptors. CJC-1295 is a GHRH analog that activates the pituitary GHRH receptor. Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist. Because they act on separate pathways, researchers study them together — one provides the “release signal,” the other amplifies the pulse. *Sold for research use only.*

## The core distinction

The simplest framing: **CJC-1295 tells the pituitary to make GH (GHRH pathway); Ipamorelin tells it to release a pulse (ghrelin pathway).** Activating one receptor produces a modest GH pulse; activating both at once is studied for a markedly larger, synergistic response than either alone.

## Side-by-side

| | CJC-1295 | Ipamorelin |
| --- | --- | --- |
| **Class** | GHRH analog (growth-hormone-releasing hormone) | GHRP / selective ghrelin-receptor agonist |
| **Receptor** | Pituitary GHRH receptor | Ghrelin receptor (GHS-R1a) |
| **Studied mechanism** | Sustained GHRH-type signaling; raises baseline GH/IGF-1 tone | Selective GH-pulse release with minimal cortisol/prolactin effect |
| **DAC vs no-DAC** | DAC version has a multi-day half-life (sustained); no-DAC is short-acting | Single short-acting form |
| **Research framing** | “Signal / baseline elevation” | “Pulse / selective release” |

## Mechanisms in more detail

**CJC-1295** is a synthetic GHRH analog that binds the pituitary GHRH receptor with high affinity to stimulate GH synthesis and release. The DAC (Drug Affinity Complex) version binds serum albumin, extending its half-life to several days; in published clinical research, CJC-1295 with DAC produced sustained, dose-dependent increases in plasma GH and IGF-1 from a single administration. The no-DAC version (“Mod GRF 1-29”) is short-acting, giving researchers tighter control over pulse timing.

**Ipamorelin** is a selective agonist of the ghrelin receptor (GHS-R1a) — the same pathway acylated ghrelin uses to trigger GH release from pituitary somatotrophs. Its defining research feature is *selectivity* : compared with earlier GHRPs, Ipamorelin releases GH with little effect on cortisol or prolactin, making it a cleaner tool for isolating GH-axis effects.

## Why researchers study them together

The two occupy different receptors, so combining them is studied for a synergistic GH response: CJC-1295 raises the underlying GHRH signal while Ipamorelin drives a selective pulse on top of it. This dual-receptor design is why the pair is one of the most commonly referenced GH-research combinations. PTW offers both individually.

## Frequently asked questions

**What is the difference between CJC-1295 and Ipamorelin?**
CJC-1295 is a GHRH analog acting on the pituitary GHRH receptor; Ipamorelin is a selective ghrelin-receptor agonist. They stimulate GH through two separate pathways.

**Why are CJC-1295 and Ipamorelin studied together?**
Because they hit different receptors, combining them is researched for a synergistic GH pulse larger than either produces alone.

**What does “DAC” mean on CJC-1295?**
DAC (Drug Affinity Complex) binds albumin to extend half-life to several days. The no-DAC form is short-acting and used when tighter timing control is needed.

**What makes Ipamorelin “selective”?**
It releases GH with minimal impact on cortisol and prolactin, unlike earlier GHRPs — useful for isolating GH-axis effects in research.

**Are these for human use?**
No. Portal to Wellness sells these strictly for laboratory and research use only. Nothing here is medical advice.

## Primary-literature anchors

Cite primary sources: Teichman et al. (CJC-1295 with DAC, sustained GH/IGF-1, *Journal of Clinical Endocrinology & Metabolism* , 2006); Raun et al. (Ipamorelin, selective GH release with low cortisol/prolactin, *European Journal of Endocrinology* , 1998). Link via PubMed.

## Related research & products

- [CJC-1295 (No-DAC)](https://portaltowellness.net/shop/cjc-1295-no-dac-10mg/)
- [Ipamorelin](https://portaltowellness.net/shop/ipamorelin-10mg/)

---

*For research use only. Not for human or veterinary use, diagnosis, treatment, or prevention of any condition. Not evaluated by the FDA. Author: Charles Fowler. Last updated: May 2026.*

---

Source: https://portaltowellness.net/cjc-1295-vs-ipamorelin/
Research use only. Terms: https://portaltowellness.net/research-use-only/